Skip to main content
. 2023 Jan 18;7:e2200113. doi: 10.1200/PO.22.00113

FIG 2.

FIG 2.

Survival outcome defined by detection of cell-free methylated RASSF1A (RASSF1A-M) at diagnosis. (A and B) EFS and OS, respectively, of patients with no detectable methylated RASSF1A in the diagnostic plasma (RASSF1A-Mneg; n = 36) and patients with detectable methylated RASSF1A in the diagnostic plasma (RASSF1A-Mpos; n = 21). (C and D) EFS and OS of RASSF1A-M‒negative patients (n = 8) and RASSF1A-M‒positive patients (n = 12) with metastatic disease. Shown below each plot is the number of patients at each time point and 5-year survival with the 95% CI. cfDNA, cell-free DNA; EFS, event-free survival; OS, overall survival.